Stelara
ustekinumab
Treatment for PsoriasisMedarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
PRINCETON, N.J., December 07, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. today announced that it will receive an undisclosed milestone payment from its licensing partner, Centocor, Inc., for the submission of regulatory applications requesting approval of ustekinumab (CNTO 1275) in the United States and in Europe for the treatment of chronic moderate to severe plaque psoriasis by Centocor.
Ustekinumab is a human monoclonal antibody that binds to the cytokines IL-12 and IL-23 and was generated using Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.
"News of a first regulatory filing for approval for an antibody developed from Medarex technology is an important milestone for Medarex and marks a major achievement in translating the technology developed by our head of research, Dr. Nils Lonberg, into innovative and potentially significant treatments for many unmet medical needs," said Howard H. Pien, President and CEO of Medarex. "We believe that the ongoing development progress of ustekinumab and other antibody programs generated from Medarex's UltiMAb platform will continue to highlight the therapeutic importance and value creation opportunities of antibodies and our technology."
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to differ materially from any future results, performance
or achievements expressed or implied by such statements. Statements
that are not historical facts, including statements preceded by,
followed by, or that include the words "potential"; "believe";
"anticipate"; "intend"; "plan"; "expect"; "estimate"; "could";
"may"; or similar statements are forward-looking statements.
Medarex disclaims, however, any intent or obligation to update
these forward-looking statements. Risks and uncertainties include
risks associated with product development, unforeseen safety issues
resulting from the administration of antibody products in humans,
uncertainties concerning Centocor's activities under its agreement
with Medarex, as well as risks detailed from time to time in
Medarex's public disclosure filings with the U.S. Securities and
Exchange Commission (SEC), including its Annual Report on Form 10-K
for the fiscal year ended December 31, 2006 and its quarterly
reports on Form 10-Q. There can be no assurance that future
milestone payments will be paid, whether the product development
efforts will succeed, or whether other developed products will
receive required regulatory clearance or that, even if such
regulatory clearance were received, such products would ultimately
achieve commercial success. Copies of Medarex's public disclosure
filings are available from its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Investor Relations, Laura S. Choi, +1-609-430-2880, x2216, orCorporate Communications (media), Jean Mantuano, +1-609-430-2880, x2221,both of Medarex, Inc.
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html /
Ticker Symbol: (NASDAQ-NMS:MEDX)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Related Articles:
FDA Approves Stelara (ustekinumab) to Treat Psoriasis - September 25, 2009
FDA Extends Review Timeline for Stelara (ustekinumab) Biologic License Application by Three Months - May 27, 2009
FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application - December 19, 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months - August 8, 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis - June 18, 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA - February 4, 2008
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis - December 4, 2007
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
